ClinicalTrials.gg
CompletedNCT04556734Updated Jun 26, 2024Results posted

Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata

A Phase 2 interventional study of Etrasimod and Etrasimod in Alopecia Areata, sponsored by Pfizer. Completed at 42 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-06-26.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Alopecia Areata by Pfizer — 4 open to participants now, 8 under way, 4 of them phase 3. Alopecia Areata · Pfizer.

Enrollment
8th of 10
80 · median 175
Started
2020
with 1 other
Phase 2
3 of 17
none open now
Registered
5th of 17
by date

Among the 17 studies in Alopecia Areata by Pfizer, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2020, is one of 3 in phase 2, and was the 5th registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

4 of the 17 studies in Alopecia Areata by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Alopecia Areata by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of etrasimod monotherapy (2 milligrams [mg] and 3 mg) in participants with moderate-to-severe alopecia areata (AA).

03

Conditions studied

  • Alopecia Areata

Keywords

  • T-cell-mediated autoimmune skin disorder
  • Alopecia areata
  • Alopecia
  • APD334
  • Etrasimod
  • Hair loss
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Men or women between ≥18 and ≤70 years of age at the time of
  • Moderate-to-severe alopecia areata as assessed by a SALT score of ≥25 and \<95 at Screening and Day 1/Baseline.
  • Current episode of hair loss for ≥6 months but \<5 years
  • Stable disease condition (no significant growth of hair) in the last 6 months as assessed by the Investigator
  • Willing to keep the same hair style and color (eg, hair products, process, and timing for hair appointments) for the duration of the study

Key Exclusion Criteria:

  • History of male or female pattern hair loss >Hamilton stage III or >Ludwig stage II
  • Other types of alopecia (eg, cicatricial/scarring alopecia [including central centrifugal cicatricial alopecia], traction alopecia, or telogen effluvium) or other diseases that could cause hair loss
  • Active scalp inflammation, scalp infection, scalp psoriasis, or any other scalp condition that may interfere with the SALT assessment
  • Previous use of Janus kinase (JAK) inhibitor (oral or topical), including participation in clinical studies of JAK inhibitors
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Etrasimod 2 mg

    Drug: Etrasimod

  • Experimental
    Etrasimod 3 mg

    Drug: Etrasimod

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Etrasimod 2 mg tablet by mouth, once daily

    Also known as: APD334

  • Etrasimod 3 mg (1 mg and 2 mg tablets) by mouth, once daily

    Also known as: APD334

  • DrugPlacebo

    Etrasimod matching placebo tablet by mouth, once daily

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Severity of Alopecia Tool I (SALT I) at Week 24: DB Treatment Period

    SALT I is a well-validated metric used to determine the degree of hair loss based on the percentage (%) of scalp surface area involved on the top (40%), back (24%), left side (18%) and right side (18%) of the scalp for AA. Investigator determines the % scalp hair loss in a given quadrant, multiply this by the total scalp area delineated by that quadrant, and sum the resultant numbers for each quadrant to give the total % scalp hair loss with a maximum score of 100. Score range from 0% (no scalp hair loss) to 100% (complete scalp hair loss), higher scores indicated more scalp hair loss. Percent change from baseline in SALT I is reported in terms of Least square mean and standard error.

    Time frame: DB Treatment Period: Baseline (before dose on Day 1), Week 24

Secondary outcomes

  1. Change From Baseline in SALT I at Week 24: DB Treatment Period

    SALT I is a well-validated metric used to determine the degree of hair loss based on the percentage (%) of scalp surface area involved on the top (40%), back (24%), left side (18%) and right side (18%) of the scalp for AA. Investigator determines the % scalp hair loss in a given quadrant, multiply this by the total scalp area delineated by that quadrant, and sum the resultant numbers for each quadrant to give the total % scalp hair loss with a maximum score of 100. Score range from 0% (no scalp hair loss) to 100% (complete scalp hair loss), higher scores indicated more scalp hair loss. Change from baseline in SALT I is reported in terms of Least square mean and standard error.

    Time frame: DBT Period: Baseline, Week 24

  2. Percentage of Participants Who Achieved Greater Than or Equal to (>=) 30%, >= 50% and >=75% Improvement From Baseline in SALT I at Week 24: DB Treatment Period

    SALT I is a well-validated metric used to determine the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for alopecia areata (AA). Investigator determine the percent scalp hair loss in a given quadrant, multiply this by the total scalp area delineated by that quadrant, and sum the resultant numbers for each quadrant to give the total percent scalp hair loss with a maximum score of 100. Score range from 0 to 100, where 0 =no scalp hair loss to 100 = complete scalp hair loss, higher scores indicated more scalp hair loss. Percentage of participants who achieved \>=30%, \>=50%, \>=75% improvement from baseline in SALT I at Week 24 was reported in this outcome measure.

    Time frame: DB Treatment Period: Baseline, Week 24

Other outcomes

  1. Number of Participants With Adverse Events (AE): DB Treatment Period

    An AE is any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations based on medical significance or any diagnosis of progressive multifocal leukoencephalopathy (PML). AEs included serious AEs and all non-SAEs.

    Time frame: DB Treatment Period: From first dosing date in DB up to (before the first dosing date in OLE) or (last dosing date + 4 weeks + 3 days), whichever is earlier (maximum up to 29 weeks)

  2. Number of Participants With Adverse Events: OLE Period

    An AE is any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations based on medical significance or any diagnosis of PML. AEs included serious AEs and all non-SAEs.

    Time frame: OLE period: From first dosing date in OLE up to last dosing date + 4 weeks + 3 days (maximum up to 33 weeks)

07

Results

Posted Jun 26, 2024

Participant flow

The study consisted of a double-blind (DB) treatment period (24 weeks) followed by an open label extension (OLE) period (28 weeks). A total of 80 participants with moderate-to-severe alopecia areata (AA) were enrolled in the DB treatment period of the study. Out of 80 participants, 65 participants entered in the subsequent OLE period.

DB Treatment Period (24 Weeks)
Participant flow — DB Treatment Period (24 Weeks)
MilestoneDB Treatment Period: Etrasimod 2 mgDB Treatment Period: Etrasimod 3 mgDB Treatment Period: PlaceboOLE Period: Etrasimod 2 mg [Etrasimod 2 mg in DB Treatment Period]OLE Period: Etrasimod 2 mg [Placebo in DB Treatment Period]OLE Period: Etrasimod 3 mg [Etrasimod 3 mg in DB Treatment Period]OLE Period: Etrasimod 3 mg [Etrasimod 2 mg in DB Treatment Period]OLE Period: Etrasimod 3 mg [Placebo in DB Treatment Period]
Started31252400000
Treated31252300000
Completed24241700000
Not completed71700000
Withdrew: Withdrawal by subject41500000
Withdrew: Protocol violation10000000
Withdrew: Lost to follow-up10100000
Withdrew: Adverse event10000000
Withdrew: Randomized but not treated00100000
OLE Period (28 Weeks)
Participant flow — OLE Period (28 Weeks)
MilestoneDB Treatment Period: Etrasimod 2 mgDB Treatment Period: Etrasimod 3 mgDB Treatment Period: PlaceboOLE Period: Etrasimod 2 mg [Etrasimod 2 mg in DB Treatment Period]OLE Period: Etrasimod 2 mg [Placebo in DB Treatment Period]OLE Period: Etrasimod 3 mg [Etrasimod 3 mg in DB Treatment Period]OLE Period: Etrasimod 3 mg [Etrasimod 2 mg in DB Treatment Period]OLE Period: Etrasimod 3 mg [Placebo in DB Treatment Period]
Started00044242013
Treated00044242013
Completed0002121199
Not completed00023314
Withdrew: Not reported00000100
Withdrew: Lost to follow-up00000002
Withdrew: Adverse event00010002
Withdrew: Withdrawal by subject00013210

Outcome measures

PrimaryPercent Change From Baseline in Severity of Alopecia Tool I (SALT I) at Week 24: DB Treatment Period

SALT I is a well-validated metric used to determine the degree of hair loss based on the percentage (%) of scalp surface area involved on the top (40%), back (24%), left side (18%) and right side (18%) of the scalp for AA. Investigator determines the % scalp hair loss in a given quadrant, multiply this by the total scalp area delineated by that quadrant, and sum the resultant numbers for each quadrant to give the total % scalp hair loss with a maximum score of 100. Score range from 0% (no scalp hair loss) to 100% (complete scalp hair loss), higher scores indicated more scalp hair loss. Percent change from baseline in SALT I is reported in terms of Least square mean and standard error.

Time frame:
DB Treatment Period: Baseline (before dose on Day 1), Week 24
Reported as:
Least squares mean · Percent change of scalp surface area
Percent Change From Baseline in Severity of Alopecia Tool I (SALT I) at Week 24: DB Treatment Period
Percent change of scalp surface areaDB Treatment Period: Etrasimod 2 mgDB Treatment Period: Etrasimod 3 mgDB Treatment Period: Placebo
Percent Change From Baseline in Severity of Alopecia Tool I (SALT I) at Week 24: DB Treatment Period-13.79 ± 8.557-21.43 ± 6.9260.35 ± 8.933
Statistical analysis
  • DB Treatment Period: Etrasimod 2 mg vs DB Treatment Period: Placebo · Mixed Models Analysis · p = 0.2579 · Ls mean difference: -14.14 · 95% CI -38.933 to 10.648
  • DB Treatment Period: Etrasimod 3 mg vs DB Treatment Period: Placebo · Mixed Models Analysis · p = 0.0592 · Ls mean difference: -21.79 · 95% CI -44.446 to 0.871
SecondaryChange From Baseline in SALT I at Week 24: DB Treatment Period

SALT I is a well-validated metric used to determine the degree of hair loss based on the percentage (%) of scalp surface area involved on the top (40%), back (24%), left side (18%) and right side (18%) of the scalp for AA. Investigator determines the % scalp hair loss in a given quadrant, multiply this by the total scalp area delineated by that quadrant, and sum the resultant numbers for each quadrant to give the total % scalp hair loss with a maximum score of 100. Score range from 0% (no scalp hair loss) to 100% (complete scalp hair loss), higher scores indicated more scalp hair loss. Change from baseline in SALT I is reported in terms of Least square mean and standard error.

Time frame:
DBT Period: Baseline, Week 24
Reported as:
Least squares mean · % of scalp surface area
Change From Baseline in SALT I at Week 24: DB Treatment Period
% of scalp surface areaDB Treatment Period: Etrasimod 2 mgDB Treatment Period: Etrasimod 3 mgDB Treatment Period: Placebo
Change From Baseline in SALT I at Week 24: DB Treatment Period-8.87 ± 4.142-8.62 ± 3.3510.36 ± 4.314
Statistical analysis
  • DB Treatment Period: Etrasimod 2 mg vs DB Treatment Period: Placebo · Mixed Models Analysis · p = 0.1283 · Least square (ls) mean difference: -9.23 · 95% CI -21.217 to 2.748
  • DB Treatment Period: Etrasimod 3 mg vs DB Treatment Period: Placebo · Mixed Models Analysis · p = 0.1057 · Ls mean difference: -8.99 · 95% CI -19.936 to 1.962
SecondaryPercentage of Participants Who Achieved Greater Than or Equal to (>=) 30%, >= 50% and >=75% Improvement From Baseline in SALT I at Week 24: DB Treatment Period

SALT I is a well-validated metric used to determine the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for alopecia areata (AA). Investigator determine the percent scalp hair loss in a given quadrant, multiply this by the total scalp area delineated by that quadrant, and sum the resultant numbers for each quadrant to give the total percent scalp hair loss with a maximum score of 100. Score range from 0 to 100, where 0 =no scalp hair loss to 100 = complete scalp hair loss, higher scores indicated more scalp hair loss. Percentage of participants who achieved \>=30%, \>=50%, \>=75% improvement from baseline in SALT I at Week 24 was reported in this outcome measure.

Time frame:
DB Treatment Period: Baseline, Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Greater Than or Equal to (>=) 30%, >= 50% and >=75% Improvement From Baseline in SALT I at Week 24: DB Treatment Period
Percentage of participantsDB Treatment Period: Etrasimod 2 mgDB Treatment Period: Etrasimod 3 mgDBT Period: Placebo
>= 30% Improvement23.5 (6.81 to 49.90)36.0 (17.97 to 57.48)12.5 (1.55 to 38.35)
>= 50% Improvement11.8 (1.46 to 36.44)28.0 (12.07 to 49.39)12.5 (1.55 to 38.35)
>= 75% Improvement5.9 (0.15 to 28.69)12.0 (2.55 to 31.22)0.000 (0.00 to 20.59)
Statistical analysis
  • DB Treatment Period: Etrasimod 2 mg vs DBT Period: Placebo · Cochran-Mantel-Haenszel · p = 0.4067 (P-values were based on the comparison of etrasimod versus placebo.) · Response rate difference: 11.5 · 95% CI -14.22 to 37.31Clopper-Pearson method
  • DB Treatment Period: Etrasimod 3 mg vs DBT Period: Placebo · Cochran-Mantel-Haenszel · p = 0.2171 (P-values were based on the comparison of etrasimod versus placebo.) · Response rate difference: 17.5 · 95% CI -8.23 to 43.19Clopper-Pearson method
  • DB Treatment Period: Etrasimod 2 mg vs DBT Period: Placebo · Cochran-Mantel-Haenszel · p = 0.9425 (P-values were based on the comparison of etrasimod versus placebo.) · Response rate difference: -0.8 · 95% CI -23.18 to 21.48Clopper-Pearson method
  • DB Treatment Period: Etrasimod 3 mg vs DBT Period: Placebo · Cochran-Mantel-Haenszel · p = 0.4959 (P-values were based on the comparison of etrasimod versus placebo.) · Response rate difference: 8.9 · 95% CI -15.19 to 32.94Clopper-Pearson method
  • DB Treatment Period: Etrasimod 2 mg vs DBT Period: Placebo · Cochran-Mantel-Haenszel · p = 0.3576 (P-values are based on the comparison of Etrasimod versus placebo.) · Response rate difference: 5.6 · 95% CI -5.39 to 16.59Clopper-Pearson method
  • DB Treatment Period: Etrasimod 3 mg vs DBT Period: Placebo · Cochran-Mantel-Haenszel · p = 0.2904 (P-values were based on the comparison of etrasimod versus placebo.) · Response rate difference: 8.3 · 95% CI -3.43 to 20.12Clopper-Pearson method
Other pre-specifiedNumber of Participants With Adverse Events (AE): DB Treatment Period

An AE is any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations based on medical significance or any diagnosis of progressive multifocal leukoencephalopathy (PML). AEs included serious AEs and all non-SAEs.

Time frame:
DB Treatment Period: From first dosing date in DB up to (before the first dosing date in OLE) or (last dosing date + 4 weeks + 3 days), whichever is earlier (maximum up to 29 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AE): DB Treatment Period
ParticipantsDB Treatment Period: Etrasimod 2 mgDB Treatment Period: Etrasimod 3 mgDB Treatment Period: Placebo
Number of Participants With Adverse Events (AE): DB Treatment Period212018
Other pre-specifiedNumber of Participants With Adverse Events: OLE Period

An AE is any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations based on medical significance or any diagnosis of PML. AEs included serious AEs and all non-SAEs.

Time frame:
OLE period: From first dosing date in OLE up to last dosing date + 4 weeks + 3 days (maximum up to 33 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events: OLE Period
ParticipantsOLE Period: Etrasimod 2 mg [Etrasimod 2 mg in DB Treatment Period]OLE Period: Etrasimod 2 mg [Placebo in DB Treatment Period]OLE Period: Etrasimod 3 mg [Etrasimod 3 mg in DBT]OLE Period: Etrasimod 3 mg [Etrasimod 2 mg in DB Treatment Period]OLE Period: Etrasimod 3 mg [Placebo in DB Treatment Period]
Number of Participants With Adverse Events: OLE Period32181411

Adverse events

Collected over From first dosing date up to last dosing date + 4 weeks + 3 days (maximum up to 57 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB Treatment Period: Etrasimod 2 mg0/31 (0%)0/31 (0%)11/31 (35.5%)
DB Treatment Period: Etrasimod 3 mg0/25 (0%)0/25 (0%)12/25 (48%)
DB Treatment Period: Placebo0/23 (0%)0/23 (0%)11/23 (47.8%)
OLE Period: Etrasimod 2 mg [Etrasimod 2 mg in DB Treatment Period]0/4 (0%)1/4 (25%)3/4 (75%)
OLE Period: Etrasimod 2 mg [Placebo in DB Treatment Period]0/4 (0%)0/4 (0%)2/4 (50%)
OLE Period: Etrasimod 3 mg [Etrasimod 3 mg in DB Treatment Period]0/24 (0%)1/24 (4.2%)14/24 (58.3%)
OLE Period: Etrasimod 3 mg [Etrasimod 2 mg in DB Treatment Period]0/20 (0%)0/20 (0%)11/20 (55%)
OLE Period: Etrasimod 3 mg [Placebo in DB Treatment Period]0/13 (0%)0/13 (0%)11/13 (84.6%)
Most frequent serious events
Most frequent serious events
EventDB Treatment Period: Etrasimod 2 mgDB Treatment Period: Etrasimod 3 mgDB Treatment Period: PlaceboOLE Period: Etrasimod 2 mg [Etrasimod 2 mg in DB Treatment Period]OLE Period: Etrasimod 2 mg [Placebo in DB Treatment Period]OLE Period: Etrasimod 3 mg [Etrasimod 3 mg in DB Treatment Period]OLE Period: Etrasimod 3 mg [Etrasimod 2 mg in DB Treatment Period]OLE Period: Etrasimod 3 mg [Placebo in DB Treatment Period]
COVID-19 pneumoniaInfections and infestations0/310/250/231/40/40/240/200/13
MyelopathyNervous system disorders0/310/250/230/40/41/240/200/13
RadiculopathyNervous system disorders0/310/250/230/40/41/240/200/13
Most frequent other events
Showing 10 of 46
Most frequent other events
EventDB Treatment Period: Etrasimod 2 mgDB Treatment Period: Etrasimod 3 mgDB Treatment Period: PlaceboOLE Period: Etrasimod 2 mg [Etrasimod 2 mg in DB Treatment Period]OLE Period: Etrasimod 2 mg [Placebo in DB Treatment Period]OLE Period: Etrasimod 3 mg [Etrasimod 3 mg in DB Treatment Period]OLE Period: Etrasimod 3 mg [Etrasimod 2 mg in DB Treatment Period]OLE Period: Etrasimod 3 mg [Placebo in DB Treatment Period]
COVID-19Infections and infestations1/312/253/231/40/41/241/201/13
DizzinessNervous system disorders0/312/251/230/41/40/241/200/13
Atrioventricular block second degreeCardiac disorders0/310/250/230/41/40/240/200/13
BradycardiaCardiac disorders0/310/250/230/41/40/240/200/13
Abdominal pain upperGastrointestinal disorders0/310/250/231/40/40/240/200/13
Gastrointestinal disorderGastrointestinal disorders0/310/250/231/40/40/240/200/13
Limb injuryInjury, poisoning and procedural complications0/310/250/230/41/40/240/201/13
Electrocardiogram abnormalInvestigations0/310/250/231/40/40/240/200/13
HypopnoeaRespiratory, thoracic and mediastinal disorders0/310/250/230/41/40/240/200/13
Upper respiratory tract infectionInfections and infestations1/311/253/230/40/42/242/203/13

Baseline characteristics

DB Treatment Period randomized set included all randomized participants, irrespective of whether they received any study drug. OLE Safety set (SAF) included all participants who received at least 1 dose of study drug. Participants in DB treatment period and OLE period are not exclusive. Eligible participants from DB treatment period entered OLE period after completing treatment in DB treatment period.

Age, Continuous
Age, Continuous(Years)DB Treatment Period: Etrasimod 2 mgDB Treatment Period: Etrasimod 3 mgDB Treatment Period: PlaceboOLE Period: Etrasimod 2 mg [Etrasimod 2 mg in DB Treatment Period]OLE Period: Etrasimod 2 mg [Placebo in DB Treatment Period]OLE Period: Etrasimod 3 mg [Etrasimod 3 mg in DB Treatment Period]OLE Period: Etrasimod 3 mg [Etrasimod 2 mg in DB Treatment Period]OLE Period: Etrasimod 3 mg [Placebo in DB Treatment Period]Total
DB Treatment Period36.6 ± 12.6041.7 ± 16.6343.4 ± 13.25—————40.4 ± 14.33
OLE Period———38.0 ± 14.9943.5 ± 15.6742.4 ± 16.6535.1 ± 12.1744.8 ± 11.5340.4 ± 14.35
Sex: Female, Male
Sex: Female, Male(Participants)DB Treatment Period: Etrasimod 2 mgDB Treatment Period: Etrasimod 3 mgDB Treatment Period: PlaceboOLE Period: Etrasimod 2 mg [Etrasimod 2 mg in DB Treatment Period]OLE Period: Etrasimod 2 mg [Placebo in DB Treatment Period]OLE Period: Etrasimod 3 mg [Etrasimod 3 mg in DB Treatment Period]OLE Period: Etrasimod 3 mg [Etrasimod 2 mg in DB Treatment Period]OLE Period: Etrasimod 3 mg [Placebo in DB Treatment Period]Total
DB Treatment Period — Female1621220000059
DB Treatment Period — Male15420000021
OLE Period — Female000132091346
OLE Period — Male00031411019
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DB Treatment Period: Etrasimod 2 mgDB Treatment Period: Etrasimod 3 mgDB Treatment Period: PlaceboOLE Period: Etrasimod 2 mg [Etrasimod 2 mg in DB Treatment Period]OLE Period: Etrasimod 2 mg [Placebo in DB Treatment Period]OLE Period: Etrasimod 3 mg [Etrasimod 3 mg in DB Treatment Period]OLE Period: Etrasimod 3 mg [Etrasimod 2 mg in DB Treatment Period]OLE Period: Etrasimod 3 mg [Placebo in DB Treatment Period]Total
DB Treatment Period — Hispanic or Latino4420000010
DB Treatment Period — Not Hispanic or Latino2521200000066
DB Treatment Period — Unknown or Not Reported202000004
OLE Period — Hispanic or Latino000003407
OLE Period — Not Hispanic or Latino0004421141255
OLE Period — Unknown or Not Reported000000213
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DB Treatment Period: Etrasimod 2 mgDB Treatment Period: Etrasimod 3 mgDB Treatment Period: PlaceboOLE Period: Etrasimod 2 mg [Etrasimod 2 mg in DB Treatment Period]OLE Period: Etrasimod 2 mg [Placebo in DB Treatment Period]OLE Period: Etrasimod 3 mg [Etrasimod 3 mg in DB Treatment Period]OLE Period: Etrasimod 3 mg [Etrasimod 2 mg in DB Treatment Period]OLE Period: Etrasimod 3 mg [Placebo in DB Treatment Period]Total
DB Treatment Period — American Indian or Alaska Native100000001
DB Treatment Period — Asian130000004
DB Treatment Period — Native Hawaiian or Other Pacific Islander001000001
DB Treatment Period — Black or African American2360000011
DB Treatment Period — White2516170000058
DB Treatment Period — More than one race210000003
DB Treatment Period — Unknown or Not Reported020000002
OLE Period — American Indian or Alaska Native000100001
OLE Period — Asian000103004
OLE Period — Native Hawaiian or Other Pacific Islander000010001
OLE Period — Black or African American0000132410
OLE Period — White000221516944
OLE Period — More than one race000001203
OLE Period — Unknown or Not Reported000002002
08

Study locations

42 sites
  • Investigate MD
    Scottsdale, Arizona 85255, United States
  • Dermatology Trial Associates
    Bryant, Arkansas 72022, United States
  • California Dermatology & Clinical Research Institute
    Encinitas, California 92024, United States
  • First OC Dermatology
    Fountain Valley, California 92708, United States
  • University of California,Irvine
    Irvine, California 92697, United States
  • Prospect Optometry
    Lomita, California 90717, United States
  • Torrance Clinical Research Institute,Inc.
    Lomita, California 90717, United States
  • Yale Eye Center
    New Haven, Connecticut 06511, United States
  • Yale Investigational Drug Services
    New Haven, Connecticut 06511, United States
  • Yale Center for Clinical Investigation
    New Haven, Connecticut 06519, United States
  • Yale New Haven Hospital Department of Respiratory Care
    New Haven, Connecticut 06519, United States
  • Advanced Sleep & Respiratory Institute, PA
    Daytona Beach, Florida 32117, United States
  • International Eye Associates
    Ormond Beach, Florida 32174, United States
  • Leavitt Medical Associates of Florida d/ba Ameriderm Research
    Ormond Beach, Florida 32174, United States
  • Advanced Clinical Research Institute
    Tampa, Florida 33607, United States
  • Advanced Medical Research PC
    Sandy Springs, Georgia 30328, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • Eye Surgeons of Indiana
    Indianapolis, Indiana 46260, United States
  • Magnante Eye Care (Ophthalmological Assessments)
    Lafayette, Indiana 47905, United States
  • Physicians Research Group (Administrative Office Location)
    Noblesville, Indiana 46060, United States
  • Physicians Research Group
    West Lafayette, Indiana 47906, United States
  • Randall Dermatology, PC
    West Lafayette, Indiana 47906, United States
  • Lawrence J. Green, MD LLC
    Rockville, Maryland 20850, United States
  • Michigan Center for Skin Care Research
    Clinton Township, Michigan 48038, United States
  • MediSearch Clinical Trials
    Saint Joseph, Missouri 64506, United States
  • NYC Retina- Manhattan
    New York, New York 10003, United States
  • Bobby Buka MD, PC
    New York, New York 10012, United States
  • Rochester Ophthalmological Group
    Rochester, New York 14623, United States
  • Skin Search of Rochester, Inc.
    Rochester, New York 14623, United States
  • WDC Cosmetic and Research, PLLC
    Wilmington, North Carolina 28405, United States
  • NW Dermatology Institute
    Portland, Oregon 97210, United States
  • UPMC Department of Dermatology
    Pittsburgh, Pennsylvania 15213, United States
  • UPMC Eye Center
    Pittsburgh, Pennsylvania 15213, United States
  • International Clinical Research - Tennessee LLC
    Murfreesboro, Tennessee 37130, United States
  • Progressive Clinical Research, PA
    San Antonio, Texas 78213, United States
  • The Education & Research Foundation, Inc.
    Lynchburg, Virginia 24501, United States
  • Dermatology Specialists of Spokane
    Spokane, Washington 99202, United States
  • PRINCIPLE RESEARCH SOLUTIONS (pulmonary function testing)
    Spokane, Washington 99204, United States
  • SPOKANE EYE CLINIC (OCT and optical exam
    Spokane, Washington 99204, United States
  • Dermatology Research Institute
    Calgary, Alberta T2J 7E1, Canada
  • Laser Rejuvenation Clinics Edmonton D.T. Inc.
    Edmonton, Alberta T5J 3S9, Canada
  • Innovaderm Research
    Montreal, Quebec H2X 2V1, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Jun 2023, 34 months.

Results were first posted in Jun 2024, 1 year after primary completion.

Of 30 phase 2 interventional studies under Alopecia Areata, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 34 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2020
First posted
Sep 21, 2020
StartActual
Jul 29, 2020
Primary completionActual
Jun 7, 2023
CompletionActual
Jun 7, 2023
Results first posted
Jun 26, 2024
Last update
Jun 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04556734
Lead sponsor
Pfizer
Collaborators
Arena is a wholly owned subsidiary of Pfizer
Responsible party
Sponsor
First posted
Sep 21, 2020
Start date
Jul 29, 2020
Primary completion
Jun 7, 2023
Completion
Jun 7, 2023
Results posted
Jun 26, 2024
Last update
Jun 26, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etrasimod

Start the discussion